ArticleThe American journal of tropical medicine and hygiene2016
Chronic Chagas Disease Diagnosis: A Comparative Performance of Commercial Enzyme Immunoassay Tests.
Article in The American journal of tropical medicine and hygiene, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Rapid diagnostic tests and ELISA for diagnosing chronic Chagas disease: Systematic revision and meta-analysis.PLoS neglected tropical diseases · 2022Pooled it
- Technological advances in the serological diagnosis of Chagas disease in dogs and cats: a systematic review.Parasites & vectors · 2022Pooled it
- Identifying Cardiac Autoantibody Biomarkers that Predict the Severity of Chagas Cardiomyopathy.JACC. Basic to translational science · 2026Article
- Double-antigen sandwich ELISA based on chimeric antigens for detection of antibodies to Trypanosoma cruzi in human sera - A phase II study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Standardization of Serodiagnostic Methods for Trypanosoma cruzi.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Article
- Evaluation of four chimeric Trypanosoma cruzi recombinant antigens for serological diagnosis of chronic Chagas disease in dogs: a phase II study.Parasites & vectors · 2025Article
- Diagnostic Performance of Chimeric Recombinant Antigens of Trypanosoma cruzi for Identifying Chagas Disease in Samples From Rio Grande do Sul.Tropical medicine & international health : TM & IH · 2025Article
- A New Approach for Chagas Disease Screening Using Serum Infrared Spectroscopy and Machine Learning Algorithms.ACS infectious diseases · 2025Article
- Comparison of Four Chimeric Antigens and Commercial Serological Assays for the Diagnosis of Trypanosoma cruzi Infection.The American journal of tropical medicine and hygiene · 2025Article
- The diagnostic value of two antigenic domains derived from theFrontiers in microbiology · 2025Article
- A multicentre comparative study of serological methods for diagnosing Chagas disease in Brazil.Memorias do Instituto Oswaldo Cruz · 2025Article
- Article
- Comparative evaluation of lateral flow assays to diagnose chronic Trypanosoma cruzi infection in Bolivia.PLoS neglected tropical diseases · 2024Article
- Characterization of NovelInternational journal of molecular sciences · 2024Article
- Article
- Assessment of Cross-Reactivity of ChimericDiagnostics (Basel, Switzerland) · 2023Article
- Seroepidemiology of Chagas disease in at-risk individuals in Caraíbas, a city with high endemicity in Bahia State, Brazil.Frontiers in public health · 2023Article
- A multicenter comparative study of the performance of four rapid immunochromatographic tests for the detection of anti-Frontiers in medicine · 2023Article
- Western blot using Trypanosoma cruzi chimeric recombinant proteins for the serodiagnosis of chronic Chagas disease: A proof-of-concept study.PLoS neglected tropical diseases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a significant heterogeneity in reported performance of serological assays for Chagas disease diagnosis. The conventional serology testing in laboratory diagnosis and in blood banks is unsatisfactory because of a high number of inconclusive and misclassified results. We aimed to assess the quality of four commercially available enzyme-linked immunosorbent assay tests for their ability to detect Trypanosoma cruzi antibodies in 685 sera samples. Cross-reactivity was assessed by using 748 sera from patients with unrelated diseases. Initially, we found that the reactivity index against T. cruzi antigen was statistically higher in sera from Chagas disease patients compared with those from non-chagasic patients, supporting the notion that all evaluated tests have a good discriminatory ability toward the diagnosis of T. cruzi infection in patients in the chronic phase of the disease. Although all tests were similarly sensitive for diagnosing T. cruzi infection, there were significant variations in terms of specificity and cross-reactivity among them. Indeed, we obtained divergent results when testing sera from patient with unrelated diseases, particularly leishmaniasis, with the levels of cross-reactivity being higher in tests using whole T. cruzi extracts compared with those using recombinant proteins. Our data suggest that all four tests may be used for the laboratory diagnosis and routine blood screening diagnose for Chagas disease. We also emphasize that, despite their general good performance, caution is needed when analyzing the results when these tests are performed in areas where other diseases, particularly leishmaniasis, are endemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.